P17.22 LOMUSTIN OR BEVACIZUMAB AT FIRST RECURRENCE OF GLIOBLASTOMA

Por Clement, P.M., Caenepeel, C., Beuselinck, B., Bechter, O.E.
Publicado em 2014

ROLE OF GRB2-ASSOCIATED BINDER 1 (GAB1) IN EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR)-INDUCED SIGNALING IN HEAD AND NECK SQUAMOUS CELL CARCINOMA

Por Hoeben, A., Martin, D., Clement, P. M., Cools, J., Gutkind, J. S.
Publicado em 2012

P16.07 BEVACIZUMAB AS PALLIATIVE TREATMENT OF FAMILIAL SCHWANNOMATOSIS

Por Clement, P.M., Blockmans, D., Bechter, O.E., Van Calenbergh, F., Legius, E.
Publicado em 2014

Salvage Transoral Laser Microsurgery for Radiorecurrent Laryngeal Cancer: Indications, Limits, and Outcomes

Por Meulemans, J., Delaere, P., Nuyts, S., Clement, P.M., Hermans, R., Vander Poorten, V.
Publicado no Curr Otorhinolaryngol Rep (2017)

OS5.1 Sequence of bevacizumab and lomustine in patients with first progression of a glioblastoma: phase II EORTC study 26101

Por Wick, W., Stupp, R., Gorlia, T., Bendszus, M., Brandes, A. A., Voss, M. J., Le Rhun, E., Clement, P. M., Golfinopoulos, V., van den Bent, M.
Publicado no Neuro Oncol (2016)

A randomized, phase II study of afatinib versus cetuximab in metastatic or recurrent squamous cell carcinoma of the head and neck(†)

Por Seiwert, T. Y., Fayette, J., Cupissol, D., del Campo, J. M., Clement, P. M., Hitt, R., Degardin, M., Zhang, W., Blackman, A., Ehrnrooth, E., Cohen, E. E. W.
Publicado em 2014

OS5.7 First results of the randomized phase II TAVAREC trial on temozolomide with or without bevacizumab in 1p/19q intact 1st recurrence grade II and III glioma

Por Idbaih, A., Clement, P. M., Vos, F. Y. F., Platten, M., Mulholland, P., Taphoorn, M. J. B., Lewis, L., Golfinopoulos, V., Gorlia, T., van den Bent, M. J.
Publicado no Neuro Oncol (2016)

Cisplatin, 5-fluorouracil, and cetuximab (PFE) with or without cilengitide in recurrent/metastatic squamous cell carcinoma of the head and neck: results of the randomized phase I/I...

Por Vermorken, J. B., Peyrade, F., Krauss, J., Mesía, R., Remenar, E., Gauler, T. C., Keilholz, U., Delord, J. P., Schafhausen, P., Erfán, J., Brümmendorf, T. H., Iglesias, L., Bethe, U., Hicking, C., Clement, P. M.
Publicado em 2014

Afatinib versus methotrexate in older patients with second-line recurrent and/or metastatic head and neck squamous cell carcinoma: subgroup analysis of the LUX-Head & Neck 1 trial(...

Por Clement, P. M., Gauler, T., Machiels, J. P., Haddad, R. I., Fayette, J., Licitra, L. F., Tahara, M., Cohen, E. E. W., Cupissol, D., Grau, J. J., Guigay, J., Caponigro, F., de Castro, G., de Souza Viana, L., Keilholz, U., del Campo, J. M., Cong, X. J., Ehrnrooth, E., Vermorken, J. B.
Publicado no Ann Oncol (2016)

Biomarkers predict enhanced clinical outcomes with afatinib versus methotrexate in patients with second-line recurrent and/or metastatic head and neck cancer

Por Cohen, E. E. W., Licitra, L. F., Burtness, B., Fayette, J., Gauler, T., Clement, P. M., Grau, J. J., del Campo, J. M., Mailliez, A., Haddad, R. I., Vermorken, J. B., Tahara, M., Guigay, J., Geoffrois, L., Merlano, M. C., Dupuis, N., Krämer, N., Cong, X. J., Gibson, N., Solca, F., Ehrnrooth, E., Machiels, J.-P. H.
Publicado no Ann Oncol (2017)